15Oct 2024
Depemokimab Shows Efficacy in CRSwNP Phase III Trials

Depemokimab Shows Efficacy in CRSwNP Phase III Trials

The phase III ANCHOR-1 and ANCHOR-2 trials demonstrated that depemokimab significantly improved outcomes in adults with chronic rhinosinusitis with nasal polyps (CRSwNP). Both trials achieved the co-primary endpoints of reducing total nasal polyp scores and nasal obstruction from baseline to 52 weeks. The safety profile was comparable between the depemokimab and placebo groups, with a similar incidence and severity of treatment-emergent adverse events. Depemokimab’s long-acting properties and high binding affinity to IL-5 allow for potential dosing every six months. These findings position depemokimab as a promising treatment for CRSwNP, contributing to GSK's mission of advancing therapies for type 2 inflammatory conditions. Full results will be presented at an upcoming scientific congress.

  • #general surgery
  • #pharmacology
  • #general medicine
  • #psych
  • #rheumatology
  • #pathology
  • #radiology
  • #anaesthesia
  • #psychiatry
  • #fmt
  • #emergency medicine
  • #academics
  • #nursing
  • #pharmacy
  • #trichology
  • #andrology
  • #orthopaedics
  • #critical care
  • #dermatology
  • #dentistry
  • #oncology
  • #business
  • #gastroenterology
  • #nephrology
  • #diagnostics
  • #urology
  • #ophthalmology
  • #gynaecology - ivf
  • #pediatrics
  • #neurology
  • #ent
  • #pulmonology
  • #family health
  • #cardiology
  • #endo-diabetology

Like

Save

Share